{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:42:23Z","timestamp":1794368543818,"version":"4.9.0"},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1454,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1998,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>Patients with Laron syndrome (LS) can now be treated with recombinant IGF\u2010I. We describe the development of androgenization during IGF\u2010I treatment of female LS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS<\/jats:title><jats:p>Six female patients with LS\u2014two clinically prepubertal (11.6 and 13.8 years of age) and four young adults (30 to 39 years old)\u2014underwent long\u2010term replacement treatment with recombinant IGF\u2010I. The daily doses were 150\u2003\u03bcg\/kg\/day by subcutaneous (s.c.) injection in the girls and 120\u2003\u03bcg\/kg\/day in the adult women.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Testosterone, \u03944\u2010androstenedione, LH, FSH, insulin and IGF\u2010I were determined by radioimmunoassay. Blood samples were obtained after an overnight fast before the IGF\u2010I injection. Serum IGF\u2010I was also determined 4 hours after the s.c. injections.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>During IGF\u2010I treatment, four out of the six patients (two girls and two adults) developed progressive clinical symptoms and signs of hyperandrogenism (oligo\/amenorrhoea and acne). Laboratory determinations showed a significant elevation in serum testosterone, \u03944\u2010androstenedione and LH\/FSH ratio. The hyperandrogenism occurred concomitantly with an increase in IGF\u2010I serum and a decrease in serum insulin concentrations. Reduction in IGF\u2010I dose or interruption in IGF\u2010I treatment restored androgen levels to normal values. At the same time, the acne and oligomenorrhoea resolved.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Overdosage of IGF\u2010I can lead to androgenization, a previously undescribed undesirable effect of IGF\u2010I. Long\u2010term IGF\u2010I treatment necessitates progressive adjustment of the IGF\u2010I dose to avoid overtreatment.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2265.1998.00356.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:35:20Z","timestamp":1047378920000},"page":"81-87","source":"Crossref","is-referenced-by-count":63,"title":["Development of hyperandrogenism during treatment with insulin\u2010like growth factor\u2010I (IGF\u2010I) in female patients with Laron syndrome"],"prefix":"10.1111","volume":"48","author":[{"family":"Klinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Silbergeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Eshet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Laron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-351X(96)80485-X"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.9.3312"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)60060-2"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80060-6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-61-5-873"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.2251043.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.20.8083"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-22-3-325"},{"key":"e_1_2_6_10_2","first-page":"641","article-title":"Insulin\u2010like growth factors and ovarian follicular development","volume":"13","author":"Guidice L.C.","year":"1992","journal-title":"Endocrine Reviews"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.8.2868"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000181561"},{"key":"e_1_2_6_13_2","first-page":"193","article-title":"Polycystic ovary syndrome","volume":"10","author":"Jacobs H.S.","year":"1996","journal-title":"Bailliere's Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_14_2","first-page":"144","article-title":"Long\u2010term treatment of Laron type dwarfs with insulin\u2010like growth factor I increases serum insulin\u2010like growth factor\u2014binding protein 3 in the absence of growth hormone activity","volume":"128","author":"Kanety H.","year":"1993","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","unstructured":"Kanety H. Silbergeld A. Klinger B. Karasik A. Baxter R.C. Laron Z.(1997)Long\u2010term effects of insulin\u2010like growth factor (IGF)\u2010I on serum IGF\u2010I IGF\u2010binding protein\u20103 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein.European Journal of Endocrinology in press.","DOI":"10.1530\/eje.0.1370626"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.1995.8.3.149"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019616-199301000-00005"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.5.1526"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91594-X"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(95)90231-7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(06)80120-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb01829.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90236-X"},{"key":"e_1_2_6_24_2","first-page":"757","article-title":"Laron syndrome due to a post\u2010receptor defect: response to IGF\u2010I treatment","volume":"29","author":"Laron Z.","year":"1993","journal-title":"Israel Journal of Medical Sciences"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb03513.x"},{"key":"e_1_2_6_26_2","first-page":"269","article-title":"Growth hormone resistance","volume":"12","author":"Laron Z.","year":"1990","journal-title":"Annals of Clinical Research"},{"key":"e_1_2_6_27_2","first-page":"883","article-title":"Pituitary dwarfism with high serum levels of growth hormone","volume":"4","author":"Laron Z.","year":"1968","journal-title":"Israel Journal of Medical Sciences"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-33-2-332"},{"key":"e_1_2_6_29_2","first-page":"153","article-title":"Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism","volume":"2","author":"Laron Z.","year":"1966","journal-title":"Israel Journal of Medical Sciences"},{"key":"e_1_2_6_30_2","first-page":"625","article-title":"Penis and testicular size in patients with growth hormone insufficiency","volume":"163","author":"Laron Z.","year":"1970","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442408"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-73-3-674"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308263290917"},{"key":"e_1_2_6_34_2","unstructured":"Meacham L.R. Murphy T.C. Klinger B. Erster B. Laron Z. Parks J.S.(1990) Heterogeneity of molecular defects causing Laron type dwarfism. (Abst. 1393).Proceedings of the Annual Meeting of the American Endocrine Society Atlanta GA USA pp.373."},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1986.tb26482.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)55307-2"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.7.2653"},{"key":"e_1_2_6_38_2","first-page":"27","article-title":"Puberty in 15 patients with Laron Syndrome: a longitudinal study. In Lessons from Laron Syndrome (LS) 1966\u20131992. A model of GH and IGF\u2010I action and interaction (eds. Z. Laron & J.S. Parks)","volume":"24","author":"Pertzelan A.","year":"1993","journal-title":"Pediatric and Adolescent Endocrinology"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-122-2-581"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000184637"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1994.tb13310.x"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.77.6.1563"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230424"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1986.tb03596.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.59.1503"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.1.302"},{"issue":"1","key":"e_1_2_6_47_2","first-page":"249","article-title":"Insulin demand in type I diabetes mellitus is reduced during administration of insulin\u2010like growth factor I. (Abst A56","volume":"35","author":"Zenobi P.D.","year":"1992","journal-title":"Diabetologia"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1998.00356.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1998.00356.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1998.00356.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T01:00:08Z","timestamp":1698454808000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.1998.00356.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["10.1046\/j.1365-2265.1998.00356.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.1998.00356.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,1]]}}}